Advances in viral-vector systemic cytokine gene therapy against cancer (Q37725420)

22 August 2017

1 reference

title

Advances in viral-vector systemic cytokine gene therapy against cancer (English)

1 reference

22 August 2017

0 references

Lihua Liu

1

1 reference

22 August 2017

Shijie Wang

2

1 reference

22 August 2017

Baoen Shan

3

1 reference

22 August 2017

Meixiang Sang

4

1 reference

22 August 2017

Shuang Liu

5

1 reference

22 August 2017

Guiying Wang

6

1 reference

22 August 2017

language of work or name

English

0 references

publication date

4 April 2010

1 reference

22 August 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

22 August 2017

28

1 reference

22 August 2017

3883-3887

1 reference

22 August 2017

23

1 reference

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Recombinant interferon-alpha therapy in patients with follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Immune enhancement and anti-tumour activity of IL-23.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Stability analysis for long-term storage of naked DNA: impact on nonviral in vivo gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Assessment of recombinant adenoviral vectors for hepatic gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Adenovirus as an expression vector in muscle cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4+T-cell-independent CD8+T-cell-mediated tumor control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Midkine positively regulates the proliferation of human gastric cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Replicative retroviral vectors for cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Ionizing radiation: a genetic switch for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

The end of the beginning: oncolytic virotherapy achieves clinical proof-of-concept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.041

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.03.041

1 reference

22 August 2017

1 reference